Simvastatin for alcohol-related liver scarring in stable adults
Treatments studied
Part of Digestive system, Mental health clinical trials.
This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have alcohol-related chronic liver disease with biopsy-confirmed significant scarring (Ishak fibrosis score 3 to 6) from the start or within 6 months before enrollment.
- Your liver disease is “compensated,” meaning you have not had major worsening episodes recently (no recent decompensation like severe fluid buildup or related complications).
- If you can become pregnant: you must have a negative pregnancy test and agree to very effective birth control during the study.
- You are NOT currently taking statins or fibrates (cholesterol/lipid medicines).
- You do NOT have other causes of liver disease (like hepatitis B/C, autoimmune hepatitis, Wilson disease, or hemochromatosis) and you do not have recent hepatitis C cure, certain dangerous complications, or a history of certain muscle problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
This study tests whether nicotinamide (a form of vitamin B3) can help reduce liver scarring in people with nonalcoholic fatty liver disease. You may qualify if you have moderate to severe liver scarring and are between 18 and 85 years old.
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.